Ligand Pharmaceuticals Incorporated (LGND)
Develops and licenses medicines for cancer, infections, diabetes, and other serious diseases.
$296.28-0.00%Healthcare
StockGlow Score
Bullish
BearishBullish
1 year ago+123.2%
The outlook
LGND trades at $296.28, well above both its 50- and 200-day moving averages and sitting near the upper end of its 52-week range. Analysts rate it a Strong Buy with an average target around 9% above the current price. The stock carries a trailing P/E of 38.6, reflecting a premium valuation.
What’s behind the score
Analyst consensusStrong Buy — 1.2 avg of 10 analysts
Price trendAbove its 50- & 200-day averages
52-week range85% of the way from its 52-week low to high
Price targetAvg target +9% vs current price
Analyst price target
~12-month · 10 analysts$323.30average target+9.1% vs now
Now $296.28
Low $247.00High $388.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$5.94B
52-wk high
$326.63
52-wk low
$129.55
50-day avg
$270.04
200-day avg
$218.02
Trailing P/E
38.6